Biocardia announces fda approval of cardiamp heart failure ii protocol for autologous cell therapy for ischemic heart failure

Sunnyvale, calif., nov. 14, 2023 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the food and drug administration (fda) approval of its phase iii clinical trial of its cardiamp autologous cell therapy for the treatment of patients with ischemic heart failure.
BCDA Ratings Summary
BCDA Quant Ranking